Dr. Omar Abdel-Wahab: 2021 CDP Achievement Award Winner Read more about Dr. Omar Abdel-Wahab: 2021 CDP Achievement Award Winner
Dr. Linde Miles: 2021 CDP Achievement Award Winner Read more about Dr. Linde Miles: 2021 CDP Achievement Award Winner
Dr. Courtney Jones: 2021 CDP Achievement Award Winner Read more about Dr. Courtney Jones: 2021 CDP Achievement Award Winner
Exciting new publications supported by LLS: March 2022 Thumbnail Image Read more about Exciting new publications supported by LLS: March 2022
Immune-Onc Therapeutics Receives FDA Fast Track Designation for IO-202, the First Anti-LILRB4 Myeloid Checkpoint Inhibitor, for the Treatment of Relapsed or Refractory AML Thumbnail Image Read more about Immune-Onc Therapeutics Receives FDA Fast Track Designation for IO-202, the First Anti-LILRB4 Myeloid Checkpoint Inhibitor, for the Treatment of Relapsed or Refractory AML
Secura Bio Announces Final Patient Enrolled in PRIMO Study and Inclusion of COPIKTRA® (duvelisib) in NCCN Guidelines for PTCL Thumbnail Image Read more about Secura Bio Announces Final Patient Enrolled in PRIMO Study and Inclusion of COPIKTRA® (duvelisib) in NCCN Guidelines for PTCL
Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors Thumbnail Image Read more about Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors
